Recursion Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Recursion Pharmaceuticals' es Chris Gibson , nombrado en Nov 2013, tiene una permanencia de 10.42 años. compensación anual total es $6.32M, compuesta por 7.9% salario y 92.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.083% de las acciones de la empresa, por valor de $1.49M. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 8.7 años, respectivamente.
Información clave
Chris Gibson
Chief Executive Officer (CEO)
US$8.6m
Compensación total
| Porcentaje del salario del CEO | 6.5% |
| Permanencia del CEO | 10.4yrs |
| Participación del CEO | 0.08% |
| Permanencia media de la dirección | 3yrs |
| Promedio de permanencia en la Junta Directiva | 8.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
Apr 10Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
Mar 20Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely
Jan 31
Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress
Jan 12Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues
Dec 09What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today
May 09We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth
Mar 01Recursion Pharmaceuticals: Destination Unknown
Sep 20Companies Like Recursion Pharmaceuticals (NASDAQ:RXRX) Can Afford To Invest In Growth
Jul 25Recursion gets European orphan drug designation for its REC-4881 inhibitor
Jul 21These Analysts Think Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Sales Are Under Threat
May 16Recursion Pharmaceuticals, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 14Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$9m | US$561k | -US$328m |
| Sep 30 2023 | n/a | n/a | -US$293m |
| Jun 30 2023 | n/a | n/a | -US$260m |
| Mar 31 2023 | n/a | n/a | -US$249m |
| Dec 31 2022 | US$6m | US$498k | -US$239m |
| Sep 30 2022 | n/a | n/a | -US$247m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$212m |
| Dec 31 2021 | US$674k | US$485k | -US$186m |
| Sep 30 2021 | n/a | n/a | -US$147m |
| Jun 30 2021 | n/a | n/a | -US$124m |
| Mar 31 2021 | n/a | n/a | -US$99m |
| Dec 31 2020 | US$3m | US$270k | -US$87m |
Compensación vs. Mercado: La compensación total de Chris($USD8.61M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Chris ha aumentado mientras la empresa no es rentable.
CEO
Chris Gibson (40 yo)
10.4yrs
Permanencia
US$8,613,208
Compensación
Dr. Christopher C. Gibson, also known as, Chris, Ph.D. is a Co-Founder of Recursion Pharmaceuticals Inc and serves as its Chief Executive Officer and Director since November 2013. Previously, Dr. Gibson wa...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 10.4yrs | US$8.61m | 0.082% $ 1.6m | |
| COO & President | 5.8yrs | US$4.87m | 0.090% $ 1.7m | |
| Co-Founder & Director | 11.3yrs | US$292.74k | 3.03% $ 58.6m | |
| Chief Financial Officer | 4.1yrs | US$4.51m | 0.37% $ 7.1m | |
| Chief Medical Officer | less than a year | US$4.53m | 0.0017% $ 33.6k | |
| Vice President of Finance & Accounting | no data | sin datos | sin datos | |
| Chief Technology Officer | 4.3yrs | sin datos | sin datos | |
| Senior Director of Investor Relations | 1.9yrs | sin datos | sin datos | |
| Chief Legal Officer & General Counsel | less than a year | sin datos | sin datos | |
| Chief Communications Officer | 1.9yrs | sin datos | sin datos | |
| Chief Corporate Development Officer and SVP of Business Development & Corporate Initiatives | less than a year | sin datos | sin datos | |
| Vice President of People Operations | no data | sin datos | sin datos |
3.0yrs
Permanencia media
40.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RXRX se considera experimentado (3.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 10.4yrs | US$8.61m | 0.082% $ 1.6m | |
| Co-Founder & Director | 11.3yrs | US$292.74k | 3.03% $ 58.6m | |
| Chief R&D Officer | no data | sin datos | sin datos | |
| Independent Chair of the Board | 4yrs | US$327.75k | 0.020% $ 385.5k | |
| Member of Business Advisory Panel | 9.8yrs | sin datos | sin datos | |
| Chairman of Therapeutics Advisory Board | 2.8yrs | sin datos | sin datos | |
| Independent Director | 4.1yrs | US$302.74k | 0.011% $ 211.2k | |
| Co-Founder & Independent Director | 10.4yrs | US$300.25k | 1.33% $ 25.6m | |
| Member of Scientific and Technical Advisory Board | 10yrs | sin datos | sin datos | |
| Member of Scientific & Technical Advisory Board | 10yrs | sin datos | sin datos | |
| Independent Director | 7.6yrs | US$307.74k | 0.032% $ 620.7k | |
| Independent Director | 4yrs | US$307.74k | 0.018% $ 354.8k |
8.7yrs
Permanencia media
59yo
Promedio de edad
Junta con experiencia: La junta directiva de RXRX se considera experimentada (8.7 años de antigüedad promedio).